New digital consent platform streamlines consent process
Partnership with Novartis Pharmaceuticals Canada Inc. has created a faster, easier way for patients to contribute to research听
$6M grant for new Open Science patient registry
Goal is to accelerate research and let patients know how their data is helping find treatmentsA $6M grant from Brain Canada will fund the creation of a new Open Science patient registry, to share data with researchers around the world and let patients see how their data is used to develop new treatments for neurological disorders.
Study finds obesity-related neurodegeneration mimics Alzheimer鈥檚 disease
Thinning in the right temporo-parietal cortex and left prefrontal cortex were similar in both groupsA new study led by scientists at The Neuro (Montreal Neurological Institute-Hospital) of 缅北强奸 finds a correlation between neurodegeneration in obese people and Alzheimer鈥檚 disease (AD) patients.
Neuro director to co-chair new national clinical trial initiative
Consortium brings together hundreds of researchers from 28 networks, 11 trial units across the countryToday the Canadian Institutes of Health Research (CIHR) announced funding for a new clinical trial consortium co-chaired by Dr.
Frequent genetic cause of late-onset ataxia uncovered by a Quebec-led international collaboration
Discovery will improve diagnosis and open treatment possibilities for thousands of people with this debilitating neurodegenerative condition worldwideA new study published on Dec. 14, 2022 in the New England Journal of Medicine reports the identification of a previously unknown genetic cause of a late-onset cerebellar ataxia, a discovery that will improve diagnosis and open new treatment avenues for this progressive condition.
A one-stop-shop for brain imaging
Software tool brings together multiple brain maps in one placeThe brain is a complex organ, and no one imaging mode can catch everything that鈥檚 going on inside it. Over the years, multiple 鈥渂rain maps鈥� have emerged, each focusing on different brain processes, from metabolism to cognitive function. While these maps are important, using them in isolation limits the discoveries researchers can make from them.
Quebec study on long COVID seeking participants
Purpose is to understand post-COVID symptom evolution and impact on patients鈥� livesAs of Sept. 20, 2022, there have been more than 1.1 million cases of COVID-19 in Quebec. It is estimated that 10 to 30 per cent of cases will have lingering symptoms after the acute illness. This means that as many as 330,000 Quebecers may experience what鈥檚 become known as long COVID, or post-COVID-19 syndrome.
Two Neuro faculty inducted into The Royal Society of Canada
Society recognizes distinguished Canadians who have made remarkable contributions to their academic fields and public life
Two faculty members at The Neuro (Montreal Neurological Institute-Hospital) have been inducted into The Royal Society of Canada (RSC), recognizing their contributions to our understanding of neuroscience and the human brain.
Changing how we value research
The Neuro joins two other 缅北强奸-affiliated organizations in signing The Declaration on Research AssessmentThe Neuro (Montreal Neurological Institute-Hospital) has joined the Douglas Research Centre (DRC) and the Canadian Open Neuroscience Platform (CONP) in signing the San Francisco Declaration on Research Assessment (DORA), an agreement that seeks to change how scholarly research contributions are valued in hiring, promotion, and funding decisions.
Boris Bernhardt wins CAN's 2022 New Investigator Award
Together with Dr. Birgit Frauscher, Bernhardt co-directs The Neuro鈥檚 new Centre of Excellence in EpilepsySince joining The Neuro in 2016, Boris Bernhardt, PhD, Assistant Professor of Neurology and Neurosurgery, has published pioneering research on the organization and development of the healthy brain. His achievements have been recognized this week by the Canadian Association for Neuroscience, who have awarded him the 2022 New Investigator Award.
Douglas Research Centre joins The Neuro in Open Science
Five-point strategy will maximize the impact of research and maintain leadership in mental health research and careToday the Douglas Research Centre (DRC) joins The Neuro鈥檚 Tanenbaum Open Science Institute (TOSI) as a partner in research data sharing and collaboration through the adoption of a set of institutional Open Science principles.
Largest ever psychedelics study maps changes of conscious awareness to neurotransmitter systems
Applying machine learning to a database of testimonials uncovers how drug-induced changes in subjective awareness are mechanistically rooted in the human brainPsychedelics are now a rapidly growing area of neuroscience and clinical research, one that may produce much-needed new therapies for disorders such as depression and schizophrenia. Yet there is still a lot to know about how these drug agents alter states of consciousness.
Open Science antibody characterization project receives $4-million grant
YCharOS is an independent quality assessment initiative to improve research results听An antibody characterization project with partners at The Neuro will be able to expand thanks to funding from G茅nome Qu茅bec.听听
Artificial intelligence tutoring outperforms expert instructors in neurosurgical training
Machine learning algorithms enhanced technical performance and learning outcomes during simulated brain tumor removalThe COVID-19 pandemic has presented both challenges and opportunities for medical training. Remote learning technology has become increasingly important in several fields. A new study finds that in a remote environment, an artificial intelligence (AI) tutoring system can outperform expert human instructors.
Neuro Genomics Partnership aims to drive neurological disease research
Academia and industry collaborate to find new targets for neurological disease treatmentA new research collaboration between The Neuro (Montreal Neurological Institute-Hospital), Takeda Development Center Americas, Inc. and Roche will enable large-scale analysis of patient data to potentially find promising targets for drug development in neurological diseases.
